WITH COMPLETE SOLUTIONS GRADED A++
MODULE 2
DNA damaging drugs (2)
Cyclophosphamide (DNA alkylating agent)
Cisplatin
Topoisomerase II drugs (2)
Doxorubicin, Etoposide
Microtubule drugs (2)
Vincristine
Paclitaxel
Antimetabolites (3)
Methotrexate5-Fluorouracil (5-FU)Cytosine arabinoside (Ara C)
Protein tyrosine kinase inhibitors (1)
Imatinib
Cyclophosphamide mechanism
Alkalating agent; DNA cross links
Haemorrhagic cystitis, Myelosuppression, and secondary malignancies
,Cisplatin Mechanism
DNA cross-link
Neuro and renal toxicity
Bleomycin Mechanism
Free radicals --> DNA breaks
Pulmonary fibrosis
Topotecan Mechanism
Topoisomerase I inhibitor
Myelosuppression
Doxorubicin Mechanism
Topoisomerase inhibitor II
Myelosuppression and Cardiotoxicity
Etoposide Mechanism
Topoisomerase inhibitor II
Myelosuppression
Paclitaxel
,Microtubule stabilization
Neurotoxicity, myelosuppression
Vincristine Mechanism
Disruption of microtubules
Neurotoxicity
Methotrexate Mechanism
Folate synthesis inhibitor (DHFR)
Myelosuppression and Mucositis
F-Fluorouracil Mechanism
Folate synthesis inhibitor (TS)
Myelosuppression and Mucositis
Cytarabine Mechanism
Inhibit DNA elongations
Myelosuppression
MODULE 3
Targeted Therapy
EGFR Antibodies (6)
, Cetuximab
Erlotinib/Gefitinib
Gefitinib
Osimertinib
Trastuzumab
Lapatinib
Platelet Derived Growth Factor Receptor - PDGFR
Oluratumab
Imatinib
SERMS(2)
Tamoxifen
Raloxifene
SERDS (1)
Fulvestrant
AIs (1)
Anastrozole
Antiandrogens (1)
Enzalutamide
Ionizing Radiation (6)
Ionizing Radiation
Linear Energy Transfer (LET)
External Beam Radiation